Research programme: zinc finger DNA binding protein transcription factors - Alexion astrazeneca rare disease/Sangamo Therapeutics
Alternative Names: ZF-transcription factorsLatest Information Update: 22 Dec 2023
At a glance
- Originator Alexion AstraZeneca Rare Disease; Sangamo Therapeutics
- Class Recombinant proteins; Transcription factors; Zinc finger DNA binding proteins
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 24 Nov 2023 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral) (Sangamo Therapeutics pipeline; November 2023)
- 24 Nov 2023 Preclinical trials in Frontotemporal dementia in USA (Parenteral) (Sangamo Therapeutics pipeline; November 2023)